April 26, 2023 – Release at 7:30am BST
Sophia Antipolis, France

Nicox SA FR COX))), a global ophthalmology company, today announced that studies with non-clinical data for the NCX 470 and NCX 1728 were presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held from April 23-27, 2023 April 2023 takes place in New Orleans, LA, United States.

Poster title: NCX 470, a nitric oxide (NO) donor bimatoprostprotects rabbit eyes from biochemical and functional changes associated with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of the optic disc and retina.

Retinal and optic disc vascular dysfunction in glaucoma is an important therapeutic target. Effective control of ocular blood flow can slow the progressive deterioration in retinal cell function seen in glaucoma patients. This work presents compelling new evidence of retinal cell protective activity with NCX 470 in addition to its ability to lower intraocular pressure. In particular, NCX 470 was found to reverse both hemodynamic and retinal cell impairments resulting from ET-1-induced ischemia/reperfusion injury in rabbits.

NCX 470, a novel NO-donating bimatoprost eye drop, is currently in phase 3 clinical development for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Mont Blanc, the first of two Phase 3 clinical trials, was completed and results were announced in October 2022. The second phase 3 clinical trial, Denali, is ongoing with results expected in 2025. Mont Blanc and Denali studies were designed to meet regulatory requirements for Phase 3 safety and efficacy studies to support NDA submissions in the US and China. Two new phase 3b clinical trials evaluating the dual mechanism of action (NO and prostaglandin analogue) in lowering intraocular pressure and the potential retinal benefits of NCX 470 are scheduled to begin in the first half of 2023.

Pa presentation Title: NCX 1728, a nitric oxide (NO) donating phosphodiesterase type 5…